botulinum toxin A topical (ET-01) / Eirion - LARVOL DELTA

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2 | N=280 | Completed | Sponsor: Eirion Therapeutics Inc. | Active, not recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ Feb 2024

Trial completion • Trial completion date

Advances in Topical Botulinum Therapy. (PubMed, Dermatol Surg) - "The development of a topical botulinum toxin is appealing because it overcomes multiple disadvantages observed with injectable administration and would likely result in increased clinical use of botulinum toxin. The development of EMX shows promise and merits further study."

Journal • Review • Pain

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2 | N=280 | Active, not recruiting | Sponsor: Eirion Therapeutics Inc. | Trial completion date: Apr 2024 ➔ Sep 2024

Trial completion date

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2 | N=280 | Active, not recruiting | Sponsor: Eirion Therapeutics Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2 | N=280 | Recruiting | Sponsor: Eirion Therapeutics Inc. | Active, not recruiting ➔ Recruiting

Enrollment open

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2 | N=280 | Active, not recruiting | Sponsor: Eirion Therapeutics Inc. | Trial completion date: Apr 2023 ➔ Apr 2024 | Trial primary completion date: Apr 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2 | N=280 | Active, not recruiting | Sponsor: Eirion Therapeutics Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2023 ➔ Apr 2023 | Trial primary completion date: Jan 2023 ➔ Apr 2023

Enrollment closed • Trial completion date • Trial primary completion date

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2 | N=280 | Recruiting | Sponsor: Eirion Therapeutics Inc. | N=120 ➔ 280

Enrollment change

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Eirion Therapeutics Inc. | Active, not recruiting ➔ Recruiting | Trial primary completion date: Sep 2021 ➔ Jan 2023

Enrollment open • Trial primary completion date

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2 | N=120 | Active, not recruiting | Sponsor: Eirion Therapeutics Inc. | Trial completion date: May 2022 ➔ Jan 2023

Trial completion date

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2; N=120; Active, not recruiting; Sponsor: Eirion Therapeutics Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Dec 2021 ➔ Mar 2022

Clinical • Enrollment closed • Trial completion date

ET-01 in Subjects With Lateral Canthal Lines, LCL-210 (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: Eirion Therapeutics Inc.

New P2 trial

Enhancing ectoine production by recombinant Escherichia coli through step-wise fermentation optimization strategy based on kinetic analysis. (PubMed, Bioprocess Biosyst Eng) - "In this study, the recombinant ectoine-producing Escherichia coli ET01 was constructed by introducing the ectABC operon from Halomonas venusta ZH...When the final optimized two-stage fermentation strategy was used, the ectoine titer reached 47.8 g/L, which was the highest level of ectoine produced by E. coli fermentation. The fermentation regulation strategy developed in this study might be useful for scaling up the commercial production of ectoine."

Journal

[VIRTUAL] ET01: Complex Cases in Second Trimester Abortion: The Clinical, The Ethical, The Legal  (ACOG 2021) - "This session led by MFM and Family Planning Specialists will utilize case studies to explore the clinical, ethical, and legal scenarios an obstetrician-gynecologist may encounter when offering comprehensive reproductive healthcare. Objectives: Be more familiar with aspects of clinical and surgical care involved in complex second trimester abortion. Implement strategies to navigate the ethics of complex second trimester abortion. Describe various legal issues that impact provision of second trimester abortion care."

Clinical • Obstetrics

Assessment of laser assisted delivery versus intralesional injection of botulinum toxin A in treatment of hypertrophic scars and keloids. (PubMed, Dermatol Ther) - "This study aimed to evaluate the efficacy and safety of intralesional vs topical botulinum toxin A combined with Fractional CO2 laser in the treatment of hypertrophic scars and keloids. Botulinum toxin A is a promising treatment for hypertrophic scars and keloids. The use of fractional CO2 laser as a mode of delivery enhanced the efficacy of botox in hypertrophic scars."

Journal • Fibrosis

ET01 Maternal Mortality: What Can The OB-GYN Do About It? (ACOG 2020) - No abstract available

Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia (clinicaltrials.gov) - P=N/A; N=3; Recruiting; Sponsor: Institute of Hematology & Blood Diseases Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gene Therapies • Genetic Disorders • Transplantation

Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia (clinicaltrials.gov) - P=N/A; N=3; Not yet recruiting; Sponsor: Institute of Hematology & Blood Diseases Hospital

Clinical • New trial • Gene Therapies • Genetic Disorders • Transplantation

ET-01 in Subjects With Lateral Canthal Lines, LCL-208 (clinicaltrials.gov) - P2; N=75; Completed; Sponsor: Eirion Therapeutics Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion

ET-01 in Subjects With Lateral Canthal Lines, LCL-209 (clinicaltrials.gov) - P2; N=38; Completed; Sponsor: Eirion Therapeutics Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion

Histologic Evaluation of Healing Lip Defects Treated With Injected Onabotulinum Toxin A and Topical Mitomycin C. (PubMed, J Craniofac Surg) - "Local injection of BoNT-A plus Mitomycin C followed by BoNT-A alone provided less collagen formation and fibroblastic proliferation in the healing lip defect in a rat model."

Journal

Manufacturing Scale-up and Preclinical Development of ET-01, Autologous CD34+ Cells with the BCL11A Erythroid Enhancer Edited By CRISPR/Cas9, for Patients with β-Thalassemia Major (ASH 2019) - "In vitro erythroid differentiation efficiency, HbF+ cells and γ-globin mRNA levels were similar to those observed at research scale. IND-enabling preclinical studies, including GLP studies using ET-01 manufactured at the clinical scale, are ongoing."

CD34

ET-01 in Subjects With Lateral Canthal Lines, LCL-207 (clinicaltrials.gov) - P2; N=79; Completed; Sponsor: Eirion Therapeutics Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion

ET-01 in Subjects With Lateral Canthal Lines, LCL-208 (clinicaltrials.gov) - P2; N=72; Active, not recruiting; Sponsor: Eirion Therapeutics Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed